Adenosine A3 Receptor Antagonists for the Treatment of Neuropathic Pain
Abstract
Our goal is to develop BIO-205, a highly-selective agonist for the A3 adenosine receptor subtype, as an orally-administered monotherapy analgesic for the treatment of neuropathic pain and as an adjunct for opioid analgesics that increases analgesic efficacy while blocking the opioids unwanted effects (addiction potential, tolerance, and physical dependency). To reach this goal, the current grant supports drug manufacture, the development of analytic methods to measure the drug in biologic fluids, animal safety and toxicology studies, and the preparation of requisite documentation for an application to the FDA for an Investigational New Drug (IND) designation. In the past year we have completed manufacture of the first (100 g) batch of drug, nearly completed the second batch (750 g), completed development of analytical methods, developed the protocols for the safety/toxicology studies, and have begun drafting the IND documents.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2019
- Accession Number
- AD1092580
Entities
People
- Gary J. Bennett